Ritlecitinib (Litfulo©) was approved by FDA in June this year. It is a great advancement for the treatment of severe alopecia areata. We at Chemspace created a set of BBs with a core similar to the active ingredient of the drug.   

Ritlecitinib is a kinase inhibitor. 718 individuals who had more than 50% scalp hair loss were included in the approval testing of this drug. The test results were impressive! 23% of people treated with Ritlecitinib had more than 80% scalp hair coverage after 6 months of use.    

For all the details, contact us at info@chem-space.com.